Olopatadine nasal spray for the treatment of allergicrhinitis

Peter S. Roland; Bradleyf Marple; G. Michael Wall

doi:10.1586/eci.09.89

Olopatadine nasal spray for the treatment of allergicrhinitis

Peter S. Roland, Bradleyf Marple, G. Michael Wall

Research output: Contribution to journal › Review article › peer-review

4 Scopus citations

Abstract

Olopatadine hydrochloride nasal spray (Patanase^® Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H₁-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

Original language	English (US)
Pages (from-to)	197-204
Number of pages	8
Journal	Expert review of clinical immunology
Volume	6
Issue number	2
DOIs	https://doi.org/10.1586/eci.09.89
State	Published - Mar 2010

Keywords

Allergic rhinitis
Allergic rhinosinusitis
Antihistamine
Mast cell stabilizer
Nasal spray
Olopatadine hydrochloride
Patanase

ASJC Scopus subject areas

Immunology and Allergy
Immunology

Access to Document

10.1586/eci.09.89

Cite this

@article{d0d18fff34204cedb651a3d8786f92c5,

title = "Olopatadine nasal spray for the treatment of allergicrhinitis",

abstract = "Olopatadine hydrochloride nasal spray (Patanase{\textregistered} Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.",

keywords = "Allergic rhinitis, Allergic rhinosinusitis, Antihistamine, Mast cell stabilizer, Nasal spray, Olopatadine hydrochloride, Patanase",

author = "Roland, {Peter S.} and Bradleyf Marple and Wall, {G. Michael}",

year = "2010",

month = mar,

doi = "10.1586/eci.09.89",

language = "English (US)",

volume = "6",

pages = "197--204",

journal = "Expert review of clinical immunology",

issn = "1744-666X",

publisher = "Expert Reviews Ltd.",

number = "2",

}

TY - JOUR

T1 - Olopatadine nasal spray for the treatment of allergicrhinitis

AU - Roland, Peter S.

AU - Marple, Bradleyf

AU - Wall, G. Michael

PY - 2010/3

Y1 - 2010/3

N2 - Olopatadine hydrochloride nasal spray (Patanase® Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

AB - Olopatadine hydrochloride nasal spray (Patanase® Nasal Spray, Alcon Laboratories, TX, USA) was approved by the US FDA in 2008, and is indicated for the relief of symptoms of seasonal allergic rhinitis (SAR), also referred to as allergic rhinosinusitis. Olopatadine is an antihistamine with selective H1-receptor antagonist activity. Clinical trials of olopatadine nasal spray have demonstrated safety and efficacy in the treatment of SAR patients. With an onset of action of 30 min, olopatadine nasal spray has also been shown to improve quality of life, ability to perform work and the conduct of usual activities in SAR patients.

KW - Allergic rhinitis

KW - Allergic rhinosinusitis

KW - Antihistamine

KW - Mast cell stabilizer

KW - Nasal spray

KW - Olopatadine hydrochloride

KW - Patanase

UR - http://www.scopus.com/inward/record.url?scp=77949468044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949468044&partnerID=8YFLogxK

U2 - 10.1586/eci.09.89

DO - 10.1586/eci.09.89

M3 - Review article

C2 - 20402382

AN - SCOPUS:77949468044

SN - 1744-666X

VL - 6

SP - 197

EP - 204

JO - Expert review of clinical immunology

JF - Expert review of clinical immunology

IS - 2

ER -

Olopatadine nasal spray for the treatment of allergicrhinitis

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this